Clinical Trials Directory

Trials / Completed

CompletedNCT03641209

Extremely Low Gestatonal Age Infants' Paracetamol Study

Extremely Low Gestational Age Infants' Paracetamol Study: a Randomized Trial

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Outi Aikio · Academic / Other
Sex
All
Age
96 Hours
Healthy volunteers
Not accepted

Summary

In the present trial, early, intravenous paracetamol is compared to placebo in extremely premature or low birth weight infants in order to evaluate the effect on ductal closure.

Detailed description

The purpose of this randomized, placebo-controlled, double-blind, phase 2, one center clinical trial is to study the efficacy and safety of early (\< 96 h) intravenous paracetamol in prophylactic closure of ductus arteriosus in extremely premature (gestational age \<28+0 wk, ELGA) or low birth weight (\<1000 g, ELBW) infants. The infants born extremely preterm or low birth weight are a focus of the study, since a small phase 2 study on paracetamol failed to demonstrate contraction of ductus arteriosus. In the investigator's previous cohort of ELGA/ELBW infants, the numbers of patients who needed any therapies for patent ductus arteriosus (PDA) were 29 (23%) in the paracetamol exposed group, and 90 (54%) in the control group. As demonstrated in a phase 2 study, the early paracetamol treatment induced the closure of ductus arteriosus: the mean (SD) ductal closure age was 177 (338) h in the whole paracetamol group. However, in the subgroup of ELGA infants born before 28 gestation weeks (n=14), the mean (SD) ductal closure ages in the paracetamol and placebo groups were 491 (504) h and 858 (719) h, respectively.

Conditions

Interventions

TypeNameDescription
DRUGParacetamol 10mg/mL infusion solutionIntravenous paracetamol solution for infusion
OTHERPlaceboHalf physiological saline solution as the non-active placebo solution

Timeline

Start date
2018-09-03
Primary completion
2023-11-03
Completion
2024-03-01
First posted
2018-08-21
Last updated
2024-03-15

Locations

1 site across 1 country: Finland

Source: ClinicalTrials.gov record NCT03641209. Inclusion in this directory is not an endorsement.